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Heparin-binding epidermal growth factor (HB-EGF)
and betacellulin (BTC) are activating ligands for EGF
receptor (EGFR/ErbB1) and ErbB4. To identify their
physiological functions, we disrupted mouse HB-EGF
and BTC alleles by homologous recombination. Most
HB-EGF±/± mice died before weaning, and survivors
had enlarged, dysfunctional hearts and reduced life-
spans. Although BTC±/± mice were viable and fertile
and displayed no overt defects, the lifespan of double
null HB-EGF±/±/BTC±/± mice was further reduced,
apparently due to accelerated heart failure. HB-EGF±/±
newborns had enlarged and malformed semilunar and
atrioventricular heart valves, and hypoplastic, poorly
differentiated lungs. Defective cardiac valvulogenesis
was the result of abnormal mesenchymal cell prolifer-
ation during remodeling, and was associated with dra-
matic increases in activated Smad1/5/8. Consistent
with the phenotype, HB-EGF transcripts were loca-
lized to endocardial cells lining the margins of wild-
type valves. Similarly defective valvulogenesis was
observed in newborn mice lacking EGFR and tumor
necrosis factor-a converting enzyme (TACE). These
results suggest that cardiac valvulogenesis is depend-
ent on EGFR activation by TACE-derived soluble
HB-EGF, and that EGFR signaling is required to
regulate bone morphogenetic protein signaling in this
context.
Keywords: ADAM17/betacellulin knockout/heart failure/
lung/Smad
Introduction
The epidermal growth factor (EGF)±ErbB signaling
network includes multiple polypeptide ligands of the
EGF/neuregulin superfamily, and four related tyrosine
kinase receptors, epidermal growth factor receptor
(EGFR)/ErbB1±ErbB4 (reviewed by Riese and Stern,
1998). EGF-like growth factors share a conserved receptor
binding motif and soluble forms are usually derived from
bioactive, integral membrane precursors. Besides EGF,
they include transforming growth factor a (TGFa),
amphiregulin (AR), heparin-binding epidermal growth
factor (HB-EGF), betacellulin (BTC), epiregulin and the
recently described epigen (Strachan et al., 2001). These
proteins all bind to EGFR/ErbB1, inducing receptor
dimerization, tyrosine kinase activation and downstream
signaling pathways controlling cell proliferation, differ-
entiation, survival or motility. Heparin-binding EGF and
BTC can also bind to ErbB4 (Riese et al., 1996a; Elenius
et al., 1997). EGF family members vary in their ability to
activate distinct ErbB heterodimers, and this may partly
account for differences in their bioactivities in cell culture
(Beerli and Hynes, 1996; Riese et al., 1996b; Graus-Porta
et al., 1997).
Numerous actions are ascribed to the EGF family of
growth factors, but their physiological functions are not
well understood. Hence, our laboratory has derived mice
lacking several family members individually or in com-
bination. These studies have revealed speci®c roles for
TGFa in patterning and function of hair follicles and
migration of fetal eyelid epidermis (Luetteke et al., 1993),
and for AR supported by EGF and TGFa in ductal
morphogenesis in the developing mammary gland
(Luetteke et al., 1999). Additionally, all three ligands are
required for optimal neonatal growth, in part re¯ecting
their roles in the mammary gland, as well as their
requirement for normal development and cytoprotection
of the gastrointestinal tract (Troyer et al., 2001). In
contrast, EGFR±/± mice usually die in utero, although the
timing is markedly affected by the genetic background
(Miettinen et al., 1995; Sibilia and Wagner, 1995;
Threadgill et al., 1995). However, more recent tetraploid
aggregation experiments have allowed development to
term (Sibilia et al., 1998). In comparison, the restricted or
mild phenotypes of EGF family knockouts indicate that
there is considerable redundancy or cooperativity in the
action of these ErbB ligands.
Here we report the inactivation of mouse HB-EGF and
BTC. HB-EGF was ®rst identi®ed as a heparin-binding
mitogen for ®broblasts and smooth muscle cells that was
secreted by human macrophages (Besner et al., 1990;
Higashiyama et al., 1991). It is widely distributed in
mammalian tissues, including skin, lung and heart
(reviewed by Raab and Klagsbrun, 1997). Induced at
sites of wounding, HB-EGF may also function in response
to vascular injury since it is expressed in atherosclerotic
plaques by aortic smooth muscle cells and other cell types
(Raab and Klagsbrun, 1997), and its production by
endothelial cells is induced by VEGF (Arkonac et al.,
1998) and TNFa (Yoshizumi et al., 1992). Heparin-
binding EGF is also implicated in uterine growth and
blastocyst implantation (Kennedy et al., 1993; Das et al.,
1994).
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Heparin-binding EGF is derived from a bioactive,
transmembrane precursor, proHB-EGF, which also func-
tions as the diphtheria toxin receptor in primates (Naglich
et al., 1992). ProHB-EGF interacts with tetraspanin and
other membrane proteins, and may distinctively signal
growth inhibition or apoptosis rather than the proliferative
response induced by soluble HB-EGF (reviewed by
Iwamoto and Mekada, 2000). In this light, the identity of
the protease that regulates HB-EGF shedding is an
important topic that has assumed additional signi®cance
because regulated release of soluble HB-EGF contributes
to transactivation of EGFR by G-protein-coupled recep-
tors (GPCR) (Prenzel et al., 1999). Several metallopro-
teases, including members of the A Disintegrin and
Metalloprotease (ADAM) (Izumi et al., 1998; Asakura
et al., 2002; Lemjabbar and Basbaum, 2002; Yan et al.,
2002) and matrix metalloprotease (MMP) (Suzuki et al.,
1997; Bursi et al., 2002; Yu et al., 2002) families, have
been identi®ed as putative proHB-EGF convertases.
BTC was identi®ed as a mitogen secreted by pancreatic
b-cell insulinomas (Sasada et al., 1993; Shing et al., 1993)
and it is implicated in the normal development and
function of the pancreas (reviewed in Dunbar and
Goddard, 2000). It is highly expressed in fetal pancreas,
promotes islet growth (Demeterco et al., 2000) and co-
regulates differentiation of insulin-producing cells
(Mashima et al., 1996, 1999). It also promotes b-cell
neogenesis and improves glucose tolerance in a mouse
model of diabetes (Yamamoto et al., 2000). However,
BTC is also widely expressed and additional roles in
blastocyst implantation (Das et al., 1997), gastrointestinal
function (Kallincos et al., 2000) and atherosclerosis
(Tamura et al., 2001) have been proposed.
We report here that HB-EGF±/± and BTC±/± mice are
viable and fertile, but HB-EGF±/± mice have severely
shortened lifespans and exhibit speci®c cardiac and lung
defects. These phenotypes are mimicked in mice lacking
either EGFR or tumor necrosis factor-a converting
enzyme (TACE), providing genetic evidence that these
proteins are the relevant ErbB receptor and HB-EGF
convertase, respectively.
Results
HB-EGF±/± and BTC±/± mice are viable and fertile
Mouse HB-EGF and BTC were disrupted in embryonic
stem cells by homologous recombination (Figure 1A).
HB-EGF exons 1 and 2 were replaced with PGK-Neo, thus
deleting the signal peptide and propeptide, and simultan-
eously inducing a frameshift to prevent translational read
through. BTC was inactivated by eliminating exon 3,
which encodes the ®rst two loops of the EGF-like
sequence that are critical for receptor binding. Lines of
HB-EGF±/± and BTC±/± mice were established from
targeted ES clones on a mixed C57BL/6J 3 129
background, and the desired targeting events veri®ed by
Southern blots of genomic DNA (Figure 1B) and exon-
speci®c PCR (Figure 1C). Northern blots con®rmed the
absence of the respective transcripts (Figure 1D).
The average litter size from intercrosses of HB-EGF+/±
mice was 10.2 (n = 13 litters, 132 pups), a typical size for
our colony. However, 12 neonates died in the ®rst week
after birth and genotyping of the remaining 120 pups at
weaning revealed a non-Mendelian distribution of geno-
types: 28%+/+, 62%+/± and 11%±/±. Surviving HB-EGF±/±
mice grew normally, were fertile and matings between
them produced litters of typical size at birth, suggesting
there was little to no intrauterine loss of HB-EGF±/± mice.
However, only 40% of the HB-EGF±/± offspring survived
to weaning (n = 7 litters, 20/50 pups survived) compared
with >80% of control pups (n = 5 litters, 32/39 pups
survived), reminiscent of the results of HB-EGF+/±
matings. Mammary gland morphology was normal in
HB-EGF±/± dams, and there was no functional evidence of
impaired lactation. Gastrointestinal tract architecture was
also normal in HB-EGF±/± neonates, and the body weights
of surviving HB-EGF±/± pups were within normal range
from 1 to 3 weeks of age (data not shown). Thus, increased
mortality of HB-EGF±/± mice was not ascribed to defects
in nursing or nutrient absorption.
Matings between BTC+/± parents produced offspring in
the expected Mendelian ratios (18%+/+, 56%+/±, 26%±/±;
n = 14 litters) at weaning and BTC±/± mice were viable and
grew normally. Matings between homozygous BTC±/±
mice also yielded normal sized litters. Since BTC is
implicated in the growth and development of the pancreas
(Dunbar and Goddard, 2000), we speci®cally examined
this tissue. No morphological differences were observed in
newborn pancreata, and adult BTC+/+ and BTC±/± males
responded similarly to a glucose challenge test (data not
shown). Also, expression of insulin, glucagon, cytokeratin
and amylase were normal in BTC±/± pancreata
(P.Miettinen, personal communication).
Defective cardiac valvulogenesis in HB-EGF±/± mice
Examination of newborn hearts revealed grossly enlarged
and stenotic semilunar (SL) (aortic and pulmonary) and
atrioventricular (AV) valves in all newborn HB-EGF±/±
mice (n = 14) compared with HB-EGF+/+ mice (n = 10)
(Figure 2A±F). For example, the mean area of HB-EGF±/±
aortic valves (Figure 2M) was 56.7 6 17 mm2 (n = 7)
compared with 21.9 6 4.6 mm2 (n = 5) for HB-EGF+/+
controls (P = 0.0025).
Enlarged SL, but not AV, valves were observed in
waved-2 (EGFRwa-2/wa-2) mice, which encode a kinase-
impaired EGFR mutant, and in EGFR±/± mice (Chen et al.,
2000). We examined EGFRwa-2/wa-2 hearts and con®rmed
that only SL valves were enlarged (data not shown).
However, both SL and AV valves were dramatically
enlarged in EGFR±/± hearts (Figure 2G±I). Thus, aortic
valve area in four EGFR±/± hearts was 56.6 6 15.4 mm2
compared with 16.7 6 4.5 mm2 in four control hearts
(P = 0.0286) (Figure 2M). We attribute the difference
between the two models to residual signaling by the wa-2
receptor and a lower threshold requirement in SL valves.
Abnormal valves were not observed in triple null mice
lacking AR, EGF and TGFa (Chen et al., 2000), nor in
BTC±/± hearts (data not shown). Collectively, these results
indicate that HB-EGF is uniquely required as an EGFR
ligand for cardiac valvulogenesis.
TACE±/± mice display identical heart valve defects
ADAM17/TACE is required for conversion of membrane-
anchored proTGFa to the soluble ligand (Peschon et al.,
1998; Sunnarborg et al., 2002). TACE±/± mice displayed
generalized epithelial defects reminiscent of those
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observed in EGFR±/± animals, and we showed in cell-based
and in vitro peptide assays that TACE promotes HB-EGF
processing (Sunnarborg et al., 2002). To assess whether
TACE functions as an HB-EGF convertase in vivo, we
examined the heart valves of newborn TACE-null mice.
Hearts from these mice had SL and AV valves that were
similarly enlarged compared with HB-EGF±/± and EGFR±/±
counterparts (Figure 2J±L), e.g. the mean area of TACE±/±
aortic valves was 57.5 6 29.4 mm2 compared with
20.0 6 7.4 mm2 for TACE+/+ controls (n = 4 each
genotype; P = 0.0079) (Figure 2M).
Highly localized expression of HB-EGF in valves
We examined HB-EGF expression in control hearts during
cardiac valve development, from E11.5 through E15.5.
Fig. 1. Targeted disruption of HB-EGF and BTC. (A) Schematics illustrate strategies used to inactivate the mouse HB-EGF and BTC alleles. Targeting
constructs were designed to eliminate exons (®lled boxes) 1 and 2 of the HB-EGF gene, or exon 3 of the BTC gene using genomic sequences isolated
from a mouse 129/Sv library. Heavy lines denote 5¢ and 3¢ arms of homology, and dashed lines bracket the genomic regions replaced by the Neo
cassette. Hatched boxes mark probes used to verify correct targeting, and the locations of useful restriction sites and resulting fragments are noted. B,
BglII; E, EcoRI; H, HindIII; N, NcoI; Nt, NotI; S, StuI. (B) Southern blot analyses of genomic DNAs digested with NcoI, showing results diagnostic
for wild-type, heterozygous and homozygous targeted alleles using the indicated probes. (C) Genomic PCR using exon- or Neo-speci®c primers.




HB-EGF transcripts were highly localized to the endo-
cardial cells lining the margins of AV and SL (both
aortic and pulmonary) valves, as shown at E14.5
(Figure 3A±F). Diffuse expression was also apparent
throughout the myocardium, especially at later times
(data not shown). EGFR transcripts were detected
throughout the heart, including in developing valves, but
enriched in the endocardial cushion, as shown for E14.5
(Figure 3G and H). TACE transcripts were found
throughout the heart at this same developmental stage
(Figure 3M and N), including in HB-EGF-expressing cells
at the margins of AV and SL valves. Immuno-
histochemistry con®rmed broad distribution of TACE
protein (data not shown). Thus, growth factor, receptor and
convertase are all coexpressed, consistent with the
phenotypic similarities.
Since HB-EGF binds to ErbB4 as well as EGFR, we
considered that ErbB4 might transduce HB-EGF signals
required for valvulogenesis. ErbB4 transcripts were
detected throughout the developing heart, including in
cushions and valves, as shown at E14.5 in Figure 3K and
L. This contrasts with restricted expression in the
ventricular myocardium at E10.5 (Gassmann et al.,
1995). Since ErbB4±/± embryos die early in gestation
with defects in ventricular trabeculation, it was not
possible to examine valvulogenesis in these mice.
However, the knockout has recently been rescued by
introduction of an ErbB4 transgene in heart muscle under
the control of the a-myosin heavy chain promoter, which
directs expression speci®cally to cardiomyocytes
(Tidcombe et al., 2001). We examined SL and AV valves
in these transgenic mice and found them to be of normal
Fig. 2. Similarly defective cardiac valves in HB-EGF±/±, EGFR±/± and
TACE±/± mice. (A±L) H&E sections of newborn (P1) hearts of the indi-
cated genotypes showing atrioventricular (AV) and semilunar valves
(arrows). Scale bar = 500 mm. (M) Measurement of aortic valve areas
(mm2) 6 SD of the indicated P1 mutant hearts, including those of res-
cued ErbB4±/± mice, with their respective +/+ controls. Asterisks
denote statistically signi®cant results.
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size (Figure 2M), suggesting that ErbB4 is not required for
valvulogenesis. However, we cannot exclude possible low
level expression of the transgene in valve mesenchyme
suf®cient to direct normal valvulogenesis.
We also observed ErbB3 transcripts in the cushions and
valves from E12.5 to 15.5 (Figure 3I and J), as previously
shown for earlier time points (Meyer and Birchmeier,
1995). Thus, ErbB3 could potentially in¯uence HB-EGF
signaling through heterodimerization with EGFR.
Remodeling of valves requires HB-EGF
To address the mechanism of HB-EGF action, we
compared valve development in HB-EGF±/± and
HB-EGF+/+ hearts from E12.5 to E15.5. Immature valves
(AV and PV) were comparably sized at E12.5 and E13.5 in
both genotypes, indicating that early events in valve
formation occurred normally without HB-EGF. However,
subsequent remodeling of valves was clearly perturbed.
Whereas large, immature AV (Figure 4A and B) and PV
(Figure 4E and F) valves of control hearts were remodeled
to form slender valve lea¯ets, HB-EGF±/± valves remained
enlarged throughout the period (Figure 4C, D, G and H).
The largest size reduction for HB-EGF+/+ AV valves
occurred from E13.5 to E14.5, and for PV valves from
E12.5 to E13.5 (Figure 4Q and R). In contrast, HB-EGF±/±
valves were only modestly reduced in size, remaining
36±46% larger than the control counterparts through
E15.5, differences that were signi®cant (P = 0.0286) for
AV valves at both time points and for PV valves at E15.5.
Impaired remodeling of HB-EGF±/± valves could be due
to reduced cellular apoptosis or increased cellular prolif-
eration. TUNEL assays revealed no differences in the
percentage of cells undergoing apoptosis in HB-EGF+/+
versus HB-EGF±/± valves at E14.5 or E15.5 (Figure 4S). In
contrast, the percentages of bromodeoxyuridine (BrdU)-
positive cells were signi®cantly (P = 0.0286) increased
~3.5-fold in AV valves and ~2-fold in PV valves of
HB-EGF±/± hearts at E14.5 (Figure 4T). There was no
change in the distribution of BrdU-positive cells in
HB-EGF±/± valves, which were found throughout the
valve mesenchyme. Thus, surprisingly, impaired remod-
eling of HB-EGF±/± valves was due to excessive prolifer-
ation of mesenchymal cells. Since the cardiac valves of
young HB-EGF±/± adults were even larger and more
dis®gured than comparable controls (data not shown), we
speculate that cellular proliferation continues beyond the
embryonic time points analyzed here.
To determine whether the enlarged cardiac valves of
newborn EGFR±/± and TACE±/± mice had a similar origin,
we examined the respective hearts at E15.5. For both
genotypes, AV and PV valves were signi®cantly enlarged
compared with controls, suggesting that impaired remod-
eling was also the cause of valve enlargement in these
mutants (Figure 4I±P).
Bone morphogenetic protein (BMP) signaling is
disregulated in the absence of HB-EGF
A clue to the mechanism of defective valvulogenesis came
from an initial gene array comparison performed with total
E14.5 HB-EGF+/+ and HB-EGF±/± hearts. The three genes
most strongly upregulated in mutant heart, dHAND,
Smad6 and Id-1 (data not shown), are all implicated in
BMP signaling, which is required for out¯ow tract
septation and valve development (Kim et al., 2001;
L.F.Jackson et al.
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Gaussin et al., 2002; Delot et al., 2003). Since Smad6±/±
mice have hyperplastic valves (Galvin et al., 2000) similar
to those observed here, presumably due to disregulated
BMP signaling in the absence of this inhibitor Smad, and
cell culture studies have established the potential for
EGFR inhibition of BMP signaling (Kretzschmar et al.,
1997; Nonaka et al., 1999), we speculated that defective
valvulogenesis in our mice could be due to loss of BMP
regulation. To test this, we examined activation of Smad1/
5/8 in sections of HB-EGF+/+ and HB-EGF±/± hearts using
an antibody that detects phosphorylated forms of these
BMP signaling effectors. Figure 5 reveals dramatically
higher numbers of cells staining positive for nuclear
phospho-Smad1/5/8 in pulmonary and aortic valves of
mutant hearts compared with the control tissues at E14.5.
A similar, albeit less dramatic, trend was seen in AV
valves (data not shown). In contrast, HB-EGF+/+ and
HB-EGF±/± valves showed similarly high levels of acti-
vated Smad1/5/8 in AV and aortic valves at E12.5 during
the proliferative phase of valve development (data not
shown).
HB-EGF±/± hearts are enlarged and dysfunctional
An unusually high proportion (43%) of HB-EGF±/± adult
males and females died within the ®rst year of life. At
necropsy, these mice were found to have enlarged hearts
and congested lungs, with no other apparent pathological
defects. A systematic comparison showed that the heart-
to-body weight ratios of male HB-EGF±/± mice increased
continuously from birth through 6 months of age com-
pared with wild-type controls, although the largest relative
increase occurred between 3 and 6 weeks of age (data not
shown). Examples of enlarged hearts of apparently
healthy, 6-week-old male HB-EGF±/± mice are shown in
Figure 6A±C. The mean heart-to-body weight ratio for
6-week-old HB-EGF±/± mice was 1.27 6 0.20% compared
with 0.80 6 0.03% for HB-EGF+/+ controls (n = 5 both
genotypes; P = 0.0079). At this stage, ventricular myocyte
size (Figure 6D and E) and number per unit area were not
signi®cantly different between the two genotypes, indi-
cating that enlargement was due to hypercellularity.
However, we did not observe signi®cant incorporation of
BrdU into 5-week-old hearts of either genotype, suggest-
Fig. 3. In situ detection of HB-EGF, EGFR, ErbB3, ErbB4 and TACE transcripts in wild-type cardiac valves. (A±F) HB-EGF; (G and H) EGFR;
(I and J) ErbB3; (K and L) ErbB4; (M and N) TACE. Arrows mark regions of high expression. Sense riboprobes were hybridized to con®rm speci®c
hybridization in each case (data not shown). AoV, aortic valve; bf, bright ®eld; df, dark ®eld; v, valves. Scale bars = 100 mm.
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Fig. 4. Defective remodeling of cardiac valves in mutant mouse hearts. (A±H) H&E sections of HB-EGF+/+ or HB-EGF±/± hearts showing
(A±D) atrioventricular (AV) valves or (E±H) pulmonary valves (PV) at the indicated time points. (I±P) H&E sections of heart showing AV valves or
PV valves of the indicated TACE or EGFR genotypes at E15.5. Arrows denote valves. Scale bars = 100 mm. (Q±T) Quantitative comparison of valvu-
logenesis in HB-EGF+/+ or HB-EGF±/± hearts. (Q and R) Cushion/heart ratio 6 SD at the indicated ages. (S) Percentage of TUNEL-positive cells at




ing that proliferation occurred gradually. A comparison of
transverse sections from 6-month-old male mice indicated
that further heart enlargement included a signi®cant
hypertrophic component.
To assess the functionality of HB-EGF±/± hearts, we
performed non-invasive transthoracic echocardiography
(ECG) on 5-month-old mice. Left ventricular end-diastolic
and -systolic dimensions were signi®cantly larger, con-
®rming cardiomegaly (Table I). Calculations of fractional
shortening (SF%) revealed signi®cant systolic dysfunction
in HB-EGF±/± mice, which may be observed in advanced
human aortic valve disease (although a myopathic contri-
bution to the ECG observations cannot be excluded).
Aortic dilation, a classic symptom of valvular stenosis,
was also observed in ECGs (data not shown).
Histological sections of hearts from similarly aged
HB-EGF±/± mice showed grossly enlarged and deformed
valves, and con®rmed aortic dilation. Chondrocytes and
Fig. 6. Cardiac defects in HB-EGF±/± and HB-EGF±/±/BTC±/± mice. (A) Hearts from 6-week-old male mice. (B and C) H&E-stained cross-
sections of 6-week-old (B) HB-EGF+/+ and (C) HB-EGF±/± hearts. (D and E) PAS-stained transverse sections of left ventricle cardiomyocytes.
(F) PAS-stained section of thickened aortic valve lea¯et from 6-month-old HB-EGF±/± heart. White arrow marks chondrocytes; black arrows denote
ectopic cartilage formation. (G) H&E-stained section of HB-EGF±/±/BTC±/± heart. Arrow marks a thrombus in the left atrium. (H and I) Masson
trichrome-stained sections of HB-EGF±/±/BTC±/± hearts. Arrows mark extensive intraventricular (H) or focal epicardial (I) ®brosis (blue stain) within or
on the left ventricle. v, ventricle; ao, aorta; lv, left ventricle. Scale bars = 3.5 mm (A), 1 mm (B and C), 20 mm (D and E), 100 mm (F), 1 mm (G±I).
Fig. 5. Disregulated Smad signaling in HB-EGF mutant cushions. Sections of (A and B) pulmonary valve (PV) or (C and D) aortic valve (AoV) from
E14.5 immunostained with phospho-Smad1/5/8 antibody and counterstained with hematoxylin. Arrows mark positive staining cells. Scale bar = 100 mM.
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ectopic cartilage formation were observed throughout the
aortic valve lea¯ets of HB-EGF±/± but not control hearts
(Figure 6F), possibly as a consequence of disregulated
BMP signaling in HB-EGF±/± hearts. Cartilaginous
metaplasia and ossi®cation within the out¯ow tracts of
the heart were observed in Smad6±/± mice (Galvin et al.,
2000), and in the cardiac valves of patients undergoing
valve replacement (Mohler et al., 2001).
Combined loss of BTC exacerbates heart defects
We interbred HB-EGF±/± and BTC±/± mice to generate
double nulls in order to explore redundancy or coopera-
tivity between these two EGFR/ErbB4 binding ligands.
HB-EGF±/±/BTC±/± double null mice were viable and
fertile, but displayed a signi®cantly higher rate of mortal-
ity. Most (54%) were dead by 4 months of age, and 83%
(n = 24) had died within the ®rst year. As expected, cardiac
valves of HB-EGF±/±/BTC±/± newborns were enlarged;
however, the mean aortic valve area of newborn
HB-EGF±/±/BTC±/± mice (55.8 6 8.4 mm2) was not
signi®cantly different from that of HB-EGF±/± mice
(compare with values in Figure 2M). Electrocardiograms
of 4-month-old HB-EGF±/±/BTC±/± mice con®rmed cardi-
omegaly and systolic dysfunction compared with age-
matched controls (Table I). However, adult HB-EGF±/±/
BTC±/± mice displayed certain cardiac defects rarely or
never seen in HB-EGF±/± mice. Left atrial dilation and
thrombosis (see the clot in Figure 6G), as well as marked
®brosis within and on the left ventricle near the apex were
commonly observed ante mortem in moribund
HB-EGF±/±/BTC±/± mice from 2 months of age (Figure 6H
and I). We speculate that surface ®brosis may have
resulted from friction between the HB-EGF±/±/BTC±/±
heart and the pericardium, possibly due to ventricular
dilation (Figure 6H) during end-stage heart failure. None
of these defects was observed in BTC±/± hearts. Ectopic
cartilage formation observed in HB-EGF±/± hearts was also
observed in HB-EGF±/±/BTC±/± mice, but not in BTC±/±
hearts (data not shown). Double null mice lacking
HB-EGF and AR were also generated, but did not display
aggravated heart defects or reduced lifespans relative to
HB-EGF±/± mice (data not shown).
Morphological defects and alveolar immaturity in
HB-EGF±/± lungs
We observed defects in the lungs in ~50% of HB-EGF±/±
newborns. Mesenchymal tissue between alveoli was
abnormally thickened compared with wild-type tissue
(Figure 7A and B), and HB-EGF±/± lungs (n = 9) contained
signi®cantly fewer alveoli than HB-EGF+/+ tissue (n = 6):
39.2 6 4.0 versus 28.1 6 6.7 per ®eld (P = 0.0012)
(Figure 7G). These defects, which are consistent with
HB-EGF expression in this tissue, were most striking in
pups that were clearly in distress (no milk in the stomach,
little movement), suggesting they may have contributed to
the mortality of HB-EGF±/± pups. PAS staining revealed a
much higher fraction of immature, glycogen-containing
cells in newborn HB-EGF±/± lungs compared with controls
(Figure 7C and D); conversely, fewer cells in HB-EGF±/±
lungs stained positive for the type II pneumocyte marker,
pro-surfactant C (Figure 7E and F). Similar defects have
been noted in EGFR±/± (Miettinen et al., 1995, 1997) and
TACE±/± lungs (Zhao et al., 2001), providing further
evidence of a link between TACE and HB-EGF±EGFR
signaling.
Discussion
Human heart valve defects are the most common type of
congenital heart disease (CHD) (Bartram et al., 2001).
Heart valves develop from endocardial cushions, which
form when endothelial cells in the AV and out¯ow tract
areas undergo an epithelial-to-mesenchymal transform-
ation and invade the adjacent acellular matrix. The cells
then proliferate to form cushions that subsequently give
rise to the septa of the four-chambered heart as well as the
cardiac valves (Eisenberg and Markwald, 1995; Lamers
et al., 1995). In the mouse, endocardial cushion formation
is complete by E12.5 (Lakkis and Epstein, 1998) and is
followed by cellular apoptosis and differentiation, which
remodel the cushions to slender valve lea¯ets. In mice
lacking either HB-EGF or EGFR, valvulogenesis is
disrupted, leading to thickened, stenotic valves. Thus,
our ®ndings corroborate a role for EGFR in valvulogenesis
(Chen et al., 2000), extend this requirement to AV valves
and establish that HB-EGF is uniquely required to activate
EGFR ligand in this context.
Valvulogenesis is a complex process (Srivastava and
Olson, 2000), and hence we considered various possible
explanations for the HB-EGF±/± phenotype, including
altered homing or migration of neural crest-derived cells.
However, it is unlikely that the phenotype is due to
aberrant neural crest cell migration since cushion forma-
tion, which also depends on this process, occurred
normally. In addition, defects involving neural crest cells
are typically associated with cardiac septal defects (Chien,
2000), and these are not observed in our mice. Finally,
recent evidence suggests that neural crest cells do not
Table I. Echocardiogram results for HB-EGF and HB-EGF/BTC mice
Genotype BW (g) HR (b.p.m.) IVST (mm) LVEDD (mm) LVESD (mm) PWT (mm) SF (%)
HB-EGF+/+ 38.4 6 3.9 659 6 55 0.08 6 0.03 0.32 6 0.03 0.10 6 0.02 0.1 6 0.01 68.7 6 2.7
HB-EGF±/± 35.3 6 2.3 668 6 21 0.10 6 0.03 0.41 6 0.05* 0.20 6 0.05* 0.1 6 0.02 51.6 6 7.4*
HB-EGF+/+/BTC+/+ 33.6 6 2.8 653 6 55 0.07 6 0.01 0.30 6 0.02 0.08 6 0.01 0.07 6 0.01 71.8 6 3.3
HB-EGF±/±/BTC±/± 29.0 6 2.5* 695 6 43 0.07 6 0.01 0.39 6 0.08* 0.17 6 0.10* 0.09 6 0.01 58.8 6 15.9*
Non-invasive transthoracic echocardiography was performed on unanesthetized, male mice. Values are mean 6 SD for 5-month-old HB-EGF+/+ (n = 5)
and HB-EGF±/± (n = 5) mice, and 4-month-old HB-EGF+/+/BTC+/+ (n = 6) and HB-EGF±/±/BTC±/± (n = 6) mice. BW, body weight; HR, heart rate;
IVST, interventricular septal distance; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; PWT,
posterior wall thickness; SF, fractional shortening. Asterisks denote values signi®cantly different from respective wild-type controls (P < 0.05).
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contribute to AV valves (Jiang et al., 2000), which are
similarly enlarged in our mice. Alternatively, we specu-
lated that loss of the HB-EGF precursor, which selectively
induced cellular apoptosis rather than proliferation in cell
culture (Iwamoto et al., 1999), might reduce or eliminate
cell death required for remodeling of the cardiac valves.
However, the rate of apoptosis was unchanged in
HB-EGF±/± valves during remodeling. Instead, our results
indicate that the phenotype is due to excessive or
unscheduled proliferation in the absence of HB-EGF, a
surprising ®nding.
A possible clue to the mechanism of HB-EGF/EGFR
action came from substantial evidence that cardiac valve
formation depends on signaling by BMPs, members of the
TGFb superfamily. For example, mice encoding a genet-
ically modi®ed BMP2 receptor (BMP2R) with reduced
signaling capacity displayed conspicuous defects in the
out¯ow tract of the heart. These included a lack of
conotruncal septation below the valves, interruption of the
aortic arch and a de®ciency of SL valves (Delot et al.,
2003). Similarly, double null mice lacking both BMP6 and
BMP7, as well as mice de®cient in Tolloid, a homolog of
the Drosophila metalloprotease that cleaves the BMP
antagonist, Chordin, also had hypoplastic valves (Clark
et al., 1999; Kim et al., 2001). On the other hand, mice
lacking the BMP signaling inhibitor, Smad6, had enlarged
or hyperplastic valves (Galvin et al., 2000), indicating that
Smad6 may regulate BMP2R signaling required for
cardiac valvulogenesis. These various results suggest a
model in which valves fail to form with insuf®cient BMP
signaling, but are hyperplastic when BMP signaling is
unregulated. The enlarged valves of EGFR±/± and
HB-EGF±/± mice are consistent with the hypothesis that
EGFR, activated by HB-EGF, acts to downregulate BMP
signaling in the developing valves. In the absence of either
the ligand or its receptor, excessive BMP signaling leads to
hyperproliferation. This hypothesis, which is consistent
with the ability of EGFR to regulate BMP signaling in cell
Fig. 7. A comparison of lung morphology and maturity in HB-EGF+/+ and HB-EGF±/± mice. (A and B) H&E-stained sections of newborn lungs.
Arrows point to thickened mesenchyme. (C and D) PAS-stained sections of newborn lung. Arrows (D) point to areas enriched in cells with high glyco-
gen content. (E and F) Sections of newborn lung immunostained for prosurfactant C. Arrows point to positive cells. (G) Bars indicate mean number
of alveoli counted from duplicate histological sections of newborn lung (n = 6±9 mice) of the indicated genotypes 6 SD. Asterisk denotes signi®cant
result (P = 0.0012). Scale bars = 200 mm (A and B), 100 mm (C±F).
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culture (Kretzschmar et al., 1997; Nonaka et al., 1999), in
part through phosphorylation and stabilization of the
Smad transcriptional co-repressor TGIF (Lo et al., 2001),
is supported by dramatic increases in cells staining
positive for nuclear Smad1/5/8 in the hyperplastic
HB-EGF±/± valves. To our knowledge, this is the ®rst
genetic evidence corroborating a physiological role for
mammalian EGFR in transmodulating signaling by TGFb
superfamily members.
The similarities in heart as well as lung defects
displayed by HB-EGF±/± and TACE±/± lines of mice
strongly suggest that in addition to being a proTGFa
convertase (Peschon et al., 1998; Sunnarborg et al., 2002),
TACE is also a key regulator of HB-EGF shedding. The
corollary of this conclusion is that soluble HB-EGF, not its
integral membrane precursor, is required for normal
valvulogenesis, although available reagents have not
allowed us to con®rm impaired shedding of endogenous
HB-EGF from TACE±/± cells. However, recombinant
TACE correctly cleaved a peptide substrate corresponding
to the membrane-proximal cleavage site of proHB-EGF,
and cotransfection of TACE enhanced the shedding of
exogenous HB-EGF from TACE±/± ®broblasts (Sunnarborg
et al., 2002). Hence, the combination of genetic, biochem-
ical and cell biological evidence makes a compelling case
for TACE as a physiological HB-EGF convertase. Other
metalloproteases put forward as candidate HB-EGF
convertases include MMP-3 (Suzuki et al., 1997; Bursi
et al., 2002) and MMP-7/matrilysin (Yu et al., 2002), as
well as the disintegrin metalloproteases ADAM9 (Izumi
et al., 1998), ADAM10 (Lemjabbar and Basbaum, 2002;
Yan et al., 2002) and ADAM12/meltrin a (Asakura et al.,
2002). In particular, it was recently reported that GPCR-
activated shedding of HB-EGF was blocked by a domin-
ant-negative form of ADAM12, and that a metalloprotease
inhibitor of HB-EGF shedding bound ADAM12 and
inhibited hypertrophic changes in a mouse model
(Asakura et al., 2002). However, although 30% of
ADAM12±/± mice died prior to weaning, no heart defects
were observed (Kurisaki et al., 2003). Conceivably,
ADAM12 may have a role in induced but not constitutive
shedding of HB-EGF.
Based on published reports as well as the ®ndings
reported here, it appears that all four ErbB receptors are
required for normal heart development. Genetic evidence
suggests that ErbB2 and ErbB4 form a NRG-1-activated
heterodimer necessary for ventricular trabeculation
(Gassmann et al., 1995; Lee et al., 1995; Erickson et al.,
1997), and mice lacking any of these proteins die by
E11.5. ErbB3, on the other hand, is essential for the
formation of endocardial cushions, and ErbB3±/± mice
frequently die in mid-gestation with abnormally small
cushions (Erickson et al., 1997). In contrast, HB-EGF
induced signaling by EGFR is required at a later stage for
remodeling of the cardiac valves. The requirement for
these related receptors at distinct stages of heart develop-
ment is consistent with their observed ability to
differentially activate various signaling pathways. An
important, unanswered question is whether EGFR partners
with another ErbB receptor to regulate valvulogenesis.
The lack of valve defects in rescued ErbB4 hearts suggests
that ErbB4 is not essential. The underdeveloped cushions
of ErbB3±/± hearts, on the other hand, indicate that this
receptor is required for an early step in valvulogenesis
(Camenisch et al., 2002), but do not exclude a requirement
for ErbB3, possibly in partnership with EGFR, in the later
stage of valve remodeling. Future studies should be aimed
at determining whether EGFR functions as a homo- or
heterodimer in this context, as well as deciphering the
respective mechanisms by which the four ErbB proteins
regulate distinct stages of heart development.
Materials and methods
Reagents
B6EiC3H-a/A-EGFRwa-2/wa-2Wnt3avt mice were from Jackson Laboratory
(Bar Harbor, ME). EGFR±/± mice on a CD-1 or CD-1 3 ALR.129 hybrid
background were kindly provided by David Threadgill [University of
North Carolina, Chapel Hill (UNC-CH)]. TACE+/± mice harboring the
inactivating TACEDZn mutation (Peschon et al., 1998), a gift from Jacques
Peschon and Roy Black (Immunex, Seattle, WA), were maintained on a
C57BL/6J 3 129/Sv hybrid background. Hearts from transgene rescued
ErbB4±/± mice were kindly provided by Martin Gassmann (National
Institute for Medical Research, London).
Gene targeting
HB-EGF and BTC genomic clones were isolated from a 129/Sv mouse
lambda library (Stratagene, La Jolla, CA) using a mouse HB-EGF cDNA
(kindly provided by Michael Klagsbrun, Harvard Medical School,
Boston, MA) or BTC cDNA. Plasmid pNTK was used to construct
targeting vectors as depicted in Figure 1; resulting constructs were
electroporated into R1 ES cells (Luetteke et al., 1999). Correctly targeted,
G418-resistant ES cell clones of normal karyotype were microinjected
into 3.5-day-old C57BL/6J blastocysts, which were then implanted into
pseudopregnant CD-1 foster mothers by the UNC-CH Animal Models
Core. Chimeras transmitting to germline were crossed to C57BL/6J
partners, and subsequent generations of mice maintained on a mixed
C57BL/6J 3 129/Sv background. PCR primer sequences used for
genotyping are available upon request.
Organ harvest and analysis
Neonatal mice were killed by halothane inhalation; older mice were
asphyxiated by CO2 according to IACUC guidelines. Excised organs
were ®xed in 10% buffered formalin for 48±72 h prior to paraf®n
embedding. Histological sections (5 mm) were prepared by the UNC-CH
Histopathology Core and stained as indicated. Antibodies for
immunohistochemistry were as follows: anti-Ki67 (sc-7846), Santa
Cruz Biotechnology, Santa Cruz, CA; anti-phospho-Smad1(Ser463/
465)/Smad5(Ser463/465)/Smad8(Ser462/428) (9511), Cell Signaling
Technology, Beverly, MA; and anti-prosurfactant protein C
(SURFCPabr), Research Diagnostics, Flanders, NJ. Bound antibodies
were visualized with the horseradish peroxidase-based ABC Staining
System kit (Santa Cruz Biotechnology, Santa Cruz, CA) (Schroeder and
Lee, 1998). Negative controls were obtained by incubating primary
antibodies with excess peptide immunogens prior to immunostaining.
For analysis of heart development, timed matings were performed, with
E0.5 de®ned as the morning of the day that the vaginal plug was ®rst
observed. At select gestational ages, dams were killed, and embryos
removed and ®xed in 4% paraformaldehyde for 48 h prior to paraf®n
embedding. Measurements of endocardial cushions and valves were
performed on captured hematoxylin±eosin (H&E) images using the
Bioquant software program in the UNC-CH Imaging Core (supported by
NCI grant P30-CA16086). To assess cell proliferation, pregnant dams
were injected with 100 mg/g body weight BrdU (Cell Proliferation
Labeling Reagent, Amersham Biosciences Corp., Piscataway, NJ) 2 h
prior to death. Heart sections were then stained with mouse BrdU
monoclonal antibody (Dako, Carpinteria, CA). To assess apoptosis,
TUNEL assays were performed on heart sections using the ApopTag Plus
Peroxidase in situ Apoptosis Detection kit (Intergen, Purchase, NY). The
ratios of BrdU- and TUNEL-positive cells to total cells in heart cushions
were determined for two sections per sample and averaged for statistical
analyses.
RNA analyses
RNA was isolated for northern blots using Trizol as directed (Invitrogen,
Carlsbad, CA). Samples were probed (Luetteke et al., 1999) using cloned
HB-EGF or BTC cDNAs. In situ hybridization analyses were performed
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on paraf®n sections using cDNA-derived antisense riboprobes as
described (Luetteke et al., 1999; Kornblum et al., 2000). Sense riboprobes
were hybridized for controls.
Echocardiography
Two-dimensional and M-mode imaging were performed using an ATL
HDI 5000 ultrasound system equipped with a CL10-5 CVasc/mouse scan
head (Philips Medical Systems, Andover, MA). Left ventricular end
diastolic dimension (LVEDD) and end systolic dimension (LVESD),
interventricular septum thickness (IVST) and posterior wall thickness
(PWT) were obtained from M-mode tracings. All LV dimension data are
presented as the average of two measurements. The percentage of
fractional shortening (%SF) was calculated from the equation:
%SF = (LVEDD ± LVESD)/LVEDD 3 100.
Statistical analysis
Statistical analyses were performed by UNC Lineberger Comprehensive
Cancer Center Biostatistics Core using SAS statistical software (Version
8.2; SAS Institute, Cary, NC). Exact P values were calculated for all two-
group comparisons using the non-parametric Wilcoxon two-group test.
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